LVM Capital Management Ltd. MI Invests $5.89 Million in Icon Plc (ICLR) Stock

LVM Capital Management Ltd. MI bought a new stake in Icon Plc (NASDAQ:ICLR) in the 4th quarter, HoldingsChannel reports. The firm bought 52,485 shares of the medical research company’s stock, valued at approximately $5,886,000. Icon makes up approximately 1.3% of LVM Capital Management Ltd. MI’s holdings, making the stock its 25th largest position.

A number of other large investors also recently modified their holdings of ICLR. Acrospire Investment Management LLC lifted its stake in shares of Icon by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 200 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Icon in the 3rd quarter valued at $148,000. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Icon in the 2nd quarter valued at $208,000. Commonwealth Equity Services Inc acquired a new position in shares of Icon in the 3rd quarter valued at $208,000. Finally, Holderness Investments Co. acquired a new position in shares of Icon in the 3rd quarter valued at $216,000. Institutional investors own 89.66% of the company’s stock.

Icon Plc (NASDAQ ICLR) opened at $117.81 on Thursday. Icon Plc has a 12 month low of $76.46 and a 12 month high of $124.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $6,370.00, a PE ratio of 22.88, a P/E/G ratio of 1.63 and a beta of 0.61.

Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The firm had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. During the same quarter in the prior year, the company earned $1.19 EPS. Icon’s revenue was up 4.8% on a year-over-year basis. analysts forecast that Icon Plc will post 5.37 earnings per share for the current year.

Several equities analysts have recently commented on the company. KeyCorp reaffirmed a “buy” rating and issued a $130.00 price target on shares of Icon in a research note on Thursday. Zacks Investment Research lowered Icon from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised Icon from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. SunTrust Banks reaffirmed a “buy” rating and issued a $138.00 price target on shares of Icon in a research note on Sunday, October 29th. Finally, Barclays upped their price target on Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $121.82.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.com-unik.info/2018/01/11/lvm-capital-management-ltd-mi-invests-5-89-million-in-icon-plc-iclr-stock.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit